187269-85-8

Basic information

• Product Name: 1,4-bis-[3-(3-carbomethoxymethylphenyl)-4-hydroxyphenyl]butane
• Synonyms: 1,4-bis-[3-(3-carbomethoxymethylphenyl)-4-hydroxyphenyl]butane
• CAS NO: 187269-85-8
• Molecular Weight: 538.64
• Mol File: 187269-85-8.mol

Chemical Properties

• CAS DataBase Reference: 1,4-bis-[3-(3-carbomethoxymethylphenyl)-4-hydroxyphenyl]butane(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-bis-[3-(3-carbomethoxymethylphenyl)-4-hydroxyphenyl]butane(187269-85-8)
• EPA Substance Registry System: 1,4-bis-[3-(3-carbomethoxymethylphenyl)-4-hydroxyphenyl]butane(187269-85-8)

Safety Data

• Hazardous Substances Data: 187269-85-8(Hazardous Substances Data)

Upstream product

• 6836-18-6 4-(4-methoxyphenyl) butanoyl chloride 
• 71501-17-2 1,4-bis(4-methoxyphenyl)butan-1-one 
• 5701-83-7 1,4-bis(4-methoxyphenyl)butane 
• 4521-28-2 4-(4-Methoxyphenyl)butyric acid 
• 187269-83-6 1,4-bis-[3-(3-carbomethoxymethylphenyl)-(4-methoxy)phenyl]butane 

Downstream Products

• 187269-88-1 1,4-bis-[3-(3-carbomethoxymethylphenyl)-4-(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyloxy)phenyl]butane 

Relevant articles and documents

Di- and trivalent small molecule selectin inhibitors

The present invention provides compounds having structure (II), and the pharmaceutically acceptable salts, esters, amides and prodrugs thereof.

Novel synthetic inhibitors of selectin-mediated cell adhesion: Synthesis of 1,6-bis[3-(3-carboxymethylphenyl)-4-(2-α-D-mannopyranosyloxy)phenyl] hexane (TBC1269)

Reports of a high-affinity ligand for E-selectin, sialyl di-Lewis(x) (sLe(x)Le(x), 1), motivated us to incorporate modifications to previously reported biphenyl-based inhibitors that would provide additional interactions with the protein. These compounds were assayed for the ability to inhibit the binding of sialyl Lewis(x) (sLe(x), 2) bearing HL-60 cells to E-, P-, and L- selectin fusion proteins. We report that dimeric or trimeric compounds containing multiple components of simple nonoligosaccharide selectin antagonists inhibit sLe(x)-dependent binding with significantly enhanced potency over the monomeric compound. The enhanced potency is consistent with additional binding interactions within a single selectin lectin domain; however, multivalent interaction with multiple lectin domains as a possible alternative cannot be ruled out. Compound 15e (TBC1269) showed optimal in vitro activity from this class of antagonists and is currently under development for use in the treatment of asthma.